Company Filing History:
Years Active: 2020
Title: Innovations in Hypertension Treatment by Andrew J Annalora
Introduction
Andrew J Annalora is an accomplished inventor based in Corvallis, Oregon. He has made significant contributions to the field of hypertension treatment through his innovative research and patent.
Latest Patents
Annalora holds a patent titled "Renal selective inhibition of cytochrome P450 3A5." This patent describes compositions and methods for treating hypertension in a subject. The method includes administering an antisense oligomer that effectively reduces the expression of the cytochrome P450 3A5 (CYP3A5) enzyme. The antisense oligomer can include various modified oligonucleotide backbones, such as phosphorodiamidate morpholino oligonucleotide (PMO) and phosphorothioate 2'-O-methyl oligoribonucleotides (PSO). The administration routes for the antisense oligomer can be transdermal, subcutaneous, or oral, often accompanied by a pharmaceutically acceptable carrier.
Career Highlights
Annalora is affiliated with Oregon State University, where he continues to engage in research and development in the field of pharmacology. His work focuses on innovative approaches to treat hypertension, showcasing his commitment to improving patient outcomes.
Collaborations
Throughout his career, Annalora has collaborated with notable professionals, including his coworker Patrick L I